αGPC3-DOTA

αGPC3-DOTA is a **radioimmunoconjugate** consisting of a monoclonal antibody targeting glypican-3 (GPC3), a cell surface protein highly expressed on hepatocellular carcinoma (HCC) cells, covalently linked to the chelator DOTA. This conjugate enables subsequent labeling with therapeutic or diagnostic radionuclides (notably yttrium-90 for therapy or zirconium-89 for imaging), facilitating targeted delivery of radiation to GPC3-positive tumors. The primary mechanism is antibody-mediated binding to GPC3, followed by delivery of localized ionizing radiation causing tumor cell death, demonstrated by efficacy in preclinical HCC models. The non-radiolabeled αGPC3-DOTA serves as a control to validate the dependence of antitumor efficacy on radioisotope delivery[1].

Other names

alphaGPC3-DOTAalphaGPC-3-DOTAalphaGPC 3-DOTA